Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Viral hepatitis causes an important global health burden. In 2016, the World Health Assembly adopted an objective to globally eliminate this as a public health threat by 2030. However, significant gaps exist between countries in their progress. Haiti is the last country that has introduced infant hepatitis B vaccines into the routine immunization program in the Region of the Americas, and its schedule still does not incorporate birth dose vaccines. As the first step to raise awareness of viral hepatitis in this country, we conducted a systematic review and meta-analysis to estimate the prevalence of hepatitis B (HBV), C (HCV), and D (HDV) viruses in Haiti.
Methods: We searched PubMed, EMBASE, Web of Science and Scopus for studies reporting the prevalence of HBV, HCV and HDV among Haitian, with no language restriction, published until November 30th, 2021. Prevalence was pooled a random-effects meta-analysis using a generalized linear mixed model with the logit link.
Results: Of 453 articles retrieved, 25 studies were included: 16 reported the prevalence of hepatitis B surface antigen (HBsAg), three for anti-HCV antibody, and six for both HBsAg and anti-HCV. No study was found for HDV prevalence. The pooled prevalence of HBsAg was 0.7% [95% confidence interval (CI): 0.3-1.4, = 77.7%] among children, 3.5% (95% CI: 2.8-4.4, = 93.2%) in the general adult population and 7.4% (95% CI: 4.0-13.3, = 83.9%) in high-risk adult population. The pooled prevalence of anti-HCV antibody was 0.9% (95% CI: 0.6-1.4, = 93.5%) among the general population and 1.4% (95% CI: 0.4-4.2, = 0.0%) in high-risk adult population. No study reported the prevalence of anti-HCV antibody exclusively in children.
Interpretation: The prevalence of blood-borne hepatitis, particularly that of HBV, is substantial in Haiti. The introduction of birth dose hepatitis B vaccines and improving access to testing and treatment services should be urgently considered to meet the elimination goal.
Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022298081, identifier: PROSPERO (CRD42022298081).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9874305 | PMC |
| http://dx.doi.org/10.3389/fpubh.2022.1099571 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Navigating Hepatitis C care: Knowledge gaps and access barriers among young women who inject drugs in rural Appalachia.
PLoS One
September 2025
Wake Forest University School of Medicine, Department of Implementation Science, Winston-Salem, North Carolina, United States of America.
Background: Hepatitis C virus (HCV) and injection drug use among young women are dramatically rising in the rural United States. From 2004 to 2017, heroin use among non-pregnant women increased 22.4% biennially, mirroring increases in HCV cases, especially among younger populations.
View Article and Find Full Text PDFSTI Epidemic Trajectories: From the Circle Game to Game-Changers in Prevention and Control.
Sex Transm Dis
September 2025
Departments of Global Health, Medicine, and Epidemiology, University of Washington (JN Wasserheit), National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (J Mermin and BP Stoner), and Rietmeijer Consulting (CA Rietmeijer).
Clinical Impact of Continuation Versus Cessation of Antiviral Therapy in Chronic Hepatitis B: A Modelling Study With Implications for Hepatitis B Cure.
J Viral Hepat
October 2025
Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
Discontinuing antivirals in chronic hepatitis B virus (HBV) 'e' antigen negative infection can enhance HBV surface antigen (HBsAg) loss but risks complications. We modelled the clinical impact of discontinuing antivirals in chronic HBV. We developed a Markov state model with Monte Carlo simulation of chronic HBV to compare continuation of antiviral therapy with 3 strategies of cessation and reinitiation for: (1) virologic relapse, (2) clinical relapse, or (3) hepatitis flare.
View Article and Find Full Text PDFHepatitis B Virus in Jordan: Prevalence, Incidence and Clearance From Cross-Sectional and Cohort Studies.
J Viral Hepat
October 2025
Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar.
Hepatitis B virus (HBV) infection is a global health challenge, with the World Health Organization (WHO) targeting its elimination by 2030. Jordan lacks sufficient data on HBV epidemiology, including prevalence, incidence and clearance. This study addresses these gaps through a retrospective analysis of HBV testing data from 40,268 individuals collected at Biolab Diagnostic Laboratories (2010-2024).
View Article and Find Full Text PDFBackground: Cytomegalovirus (CMV) viremia is a critical concern and known by the presence of the virus DNA in the blood, which poses sever risks and develops many complications in immuno-compromised patients. When CMV is untreated, it can cause pneumonitis, colitis, hepatitis, and encephalitis. Current diagnosis relies on molecular methods with qPCR as the preferred method.
View Article and Find Full Text PDF